ROCKAWAY, NJ , June 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10, 2021 , entitled “Effects of Transcutaneous Vagal Nerve Stimulation (tVNS/nVNS) on Cognitive
ROCKAWAY, NJ , June 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
ROCKAWAY, NJ , June 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $1.00 per
ROCKAWAY, NJ , July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger , CEO will present a company overview and be available for 1x1 meetings at the following upcoming conference: Ladenburg Thalmann
Second-Quarter 2021 revenue expected to be approximately $ 1.3 million Net cash used to fund operations in the second quarter 2021 of approximately $ 3.2 million Follow on offering subsequent to June 30, 2021 added $18 . 8 million to cash balance ROCKAWAY, NJ , July 13, 2021 (GLOBE NEWSWIRE)
ROCKAWAY, NJ , July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats , is to receive a Lifetime Achievement Award at the American Society
ROCKAWAY, NJ , July 22, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021 .
ROCKAWAY, NJ , July 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the use of a mobile
ROCKAWAY, NJ , Aug. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation and be available for virtual one-on-one meetings at the Canaccord
ROCKAWAY, NJ , Aug. 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company (the Company), today announced the release of an article entitled “gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance” in the journal